| Characteristic . | n = 21 . |
|---|---|
| Age, years; median (IQR) | 15 (11-18) |
| IBD diagnosis, Crohn’s disease; n | 16 (76%) |
| Therapy phase; n in maintenance | 19 (90.4%) |
| Weight-based dose, mg/kg; median (IQR) | 9.7 (7.9-11.2) |
| Interval, weeks; median (IQR) | 4 (4-6) |
| Maintenance trough, µg/mL; median (IQR) | 11 (5.1-23.5) |
| No. with antibodies to infliximab (ATI); n | 6 (28.6%) |
| ATI concentration, ng/mL; median (IQR) | 187 (102-270) |
| Albumin, g/dL; median (IQR) | 3.9 (3.6-4.1) |
| Paris classification; n | |
| Crohn’s location: L1, L2, L3 | 6 (37.5%), 4 (25%), 6 (37.5%) |
| Crohn’s behavior: B1, B2, B3 | 12 (75%), 1 (6.3%), 3 (18.7%) |
| Ulcerative colitis location, E4 | 5 (100%) |
| Characteristic . | n = 21 . |
|---|---|
| Age, years; median (IQR) | 15 (11-18) |
| IBD diagnosis, Crohn’s disease; n | 16 (76%) |
| Therapy phase; n in maintenance | 19 (90.4%) |
| Weight-based dose, mg/kg; median (IQR) | 9.7 (7.9-11.2) |
| Interval, weeks; median (IQR) | 4 (4-6) |
| Maintenance trough, µg/mL; median (IQR) | 11 (5.1-23.5) |
| No. with antibodies to infliximab (ATI); n | 6 (28.6%) |
| ATI concentration, ng/mL; median (IQR) | 187 (102-270) |
| Albumin, g/dL; median (IQR) | 3.9 (3.6-4.1) |
| Paris classification; n | |
| Crohn’s location: L1, L2, L3 | 6 (37.5%), 4 (25%), 6 (37.5%) |
| Crohn’s behavior: B1, B2, B3 | 12 (75%), 1 (6.3%), 3 (18.7%) |
| Ulcerative colitis location, E4 | 5 (100%) |
IQR, 25%-75% interquartile range.
| Characteristic . | n = 21 . |
|---|---|
| Age, years; median (IQR) | 15 (11-18) |
| IBD diagnosis, Crohn’s disease; n | 16 (76%) |
| Therapy phase; n in maintenance | 19 (90.4%) |
| Weight-based dose, mg/kg; median (IQR) | 9.7 (7.9-11.2) |
| Interval, weeks; median (IQR) | 4 (4-6) |
| Maintenance trough, µg/mL; median (IQR) | 11 (5.1-23.5) |
| No. with antibodies to infliximab (ATI); n | 6 (28.6%) |
| ATI concentration, ng/mL; median (IQR) | 187 (102-270) |
| Albumin, g/dL; median (IQR) | 3.9 (3.6-4.1) |
| Paris classification; n | |
| Crohn’s location: L1, L2, L3 | 6 (37.5%), 4 (25%), 6 (37.5%) |
| Crohn’s behavior: B1, B2, B3 | 12 (75%), 1 (6.3%), 3 (18.7%) |
| Ulcerative colitis location, E4 | 5 (100%) |
| Characteristic . | n = 21 . |
|---|---|
| Age, years; median (IQR) | 15 (11-18) |
| IBD diagnosis, Crohn’s disease; n | 16 (76%) |
| Therapy phase; n in maintenance | 19 (90.4%) |
| Weight-based dose, mg/kg; median (IQR) | 9.7 (7.9-11.2) |
| Interval, weeks; median (IQR) | 4 (4-6) |
| Maintenance trough, µg/mL; median (IQR) | 11 (5.1-23.5) |
| No. with antibodies to infliximab (ATI); n | 6 (28.6%) |
| ATI concentration, ng/mL; median (IQR) | 187 (102-270) |
| Albumin, g/dL; median (IQR) | 3.9 (3.6-4.1) |
| Paris classification; n | |
| Crohn’s location: L1, L2, L3 | 6 (37.5%), 4 (25%), 6 (37.5%) |
| Crohn’s behavior: B1, B2, B3 | 12 (75%), 1 (6.3%), 3 (18.7%) |
| Ulcerative colitis location, E4 | 5 (100%) |
IQR, 25%-75% interquartile range.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
